Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: U59UGK3IPC

Pharmacology

Action Mechanism of Action Reference
BINDING AGENT B-lymphocyte antigen CD20 binding agent PubMed
Primary Target
CD20 (membrane-spanning 4-domains, subfamily A, member 1)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leukemia, Lymphocytic, Chronic, B-Cell 3 D015451 ClinicalTrials
Multiple Sclerosis 3 D009103 ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting 2 D020529 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Neuromyelitis Optica 1 D009471 ClinicalTrials
Waldenstrom Macroglobulinemia 1 D008258 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1174014-05-1
ChEMBL CHEMBL2108354
FDA SRS U59UGK3IPC
Guide to Pharmacology 8920